Abstract: In this study, a poly(e-caprolactone) (PCL)/bioactive glass (BG) nanocomposite was fabricated using BG nanofibers (BGNFs) and compared with an established composite fabricated using microscale BG particles. The BGNFs were generated using sol-gel precursors via the electrospinning process, chopped into short fibers and then incorporated into the PCL organic matrix by dissolving them in a tetrahydrofuran solvent. The biological and mechanical properties of the PCL/BGNF composites were evaluated and compared with those of PCL/BG powder (BGP). Because the PCL/BG composite containing 20 wt % BG showed the highest level of alkaline phosphatase (ALP) activity, all evaluations were performed at this concentration except for that of the ALP activity itself. In vitro cell tests using the MC3T3 cell line demonstrated the enhanced biocompatibility of the PCL/BGNF composite compared with the PCL/BGP composite. Furthermore, the PCL/BGNF composite showed a significantly higher level of bioactivity compared with the PCL/BGP composite. In addition, the results of the in vivo animal experiments using Sprague-Dawley albino rats revealed the good bone regeneration capability of the PCL/BGNF composite when implanted in a calvarial bone defect. In the result of the tensile test, the stiffness of the PCL/BG composite was further increased when the BGNFs were incorporated. These results indicate that the PCL/BGNF composite has greater bioactivity and mechanical stability when compared with the PCL/BG composite and great potential as a bone regenerative material. '
INTRODUCTION
Biodegradable polymer/bioactive glass (BG) composites in the form of scaffolds and membranes have been intensively studied because of their good biocompatibility and bioactivity as hard tissue regeneration materials. [1] [2] [3] Biodegradable synthetic polymers, such as poly(glycolic acid), poly(lactic acid), poly(e-caprolactone) (PCL), and their copolymers, have been widely used as the matrices in these composites, because they have favorable biocompatibility and degradability. 4 Among these polymers, PCL is a common biodegradable, FDA-approved and low-priced biomaterial that can be easily fabricated and has proper toughness, flexibility, and biocompatibility. However, most of the polymers including PCL have limitations in bone regenerative applications because of their low stiffness, hydrophobic nature, and lack of bioactivity. To overcome the drawbacks of those biodegradable polymers, various bioactive inorganic phases, such as BG, hydroxyapatite, tricalcium phosphate, and their biphasic mixtures, have been incorporated into the polymer matrix, and this was found to improve the mechanical and biological properties of the composites. [5] [6] [7] [8] In particular, silicabased BG has been considered to be a promising bone regenerative material because of its excellent biocompatibility and bioactivity. It is well known that BGs have excellent bioactivity, that is, they can bond to surrounding bone tissues by the formation of a surface hydroxycarbonate apatite layer in the process of their chemical reactions in body fluids and can promote bone regeneration. 9 In an effort to utilize this capability of BGs, various composites reinforced with BG particles, such as PLAGA/BG, poly (e-caprolactone-co-DL-lactide)/BG and PLLA/BG, have been reported. 3, 10, 11 The composites containing BG showed favorable osteoblastic responses, potential bone bonding ability in vitro, good biocompatibility in vivo, and enhanced mechanical properties.
Furthermore, nowadays, the incorporation of BG nanofillers is being considered as a promising process in composite biomaterials. When compared with microfillers, BG nanofillers with their larger specific surface area have a more favorable influence on organic-based composites, resulting in nanostructured composites with improved bioactivity. 12 In particular, BG nanofibers (BGNF) have been shown to exhibit excellent bioactivity and to have potential applications in various types of biomaterials, such as fibrous membranes, porous scaffolds, and nanocomposites with biopolymers. 13 BGNFs with various diameters can be generated easily via the electrospinning process using sol-gel precursors. The extremely large surface area of the BGNF promotes the chemical reactions in the medium, which enables the fast formation of bone-like minerals and bone regeneration. In addition to their large surface area, BGNFs have a very high length-to-diameter ratio compared with the bulk BGs. Generally, fibers are inherently much stiffer and stronger than the same material in the bulk form. For this reason, these fibrous materials are used as reinforcing phases to enhance the strength and stiffness of the composite. In this study, a PCL/BGNF composite was fabricated to enhance the biological and mechanical properties of the PCL/BG composite by utilizing the advantages of the electrospun BGNFs, and was characterized in comparison with the composite with the microparticulate form of the BG.
EXPERIMENTAL PROCEDURE Preparation of BGNF
The composition of the BG fiber in this study was 60% SiO 2 , 36% CaO, and 4% P 2 O 5 in mole percent. The glass precursors were prepared by mixing tetraethyl orthosilicate, calcium nitrate tetrahydrate, and triethylphosphate (all from Sigma-Aldrich, USA) at appropriate ratios in a mixture of ethanol and water. A 1 N HCl solution was added as a catalyst for the hydrolysis. After stirring at room temperature for 48 h, the sol was aged in an oven at 408C for 48 h and further aged at 708C for 3 h. The aged sol was then mixed with 8% poly(vinyl butyral-co-vinyl alcohol-co-vinyl acetate) (PVB; Sigma-Aldrich, USA) at a BG sol:PVB solution ratio of 5:4 by volume to adjust its rheological properties during the electrospinning process. The sol/PVB mixture was loaded in a syringe and injected into a rotating mandrel under a DC electric field of 1.2 kV/cm at an injection rate of 0.1 mL/h. The electrospun nanofibers were heat treated at 7008C for 1 h at a rate of 28C/min to eliminate the organic sources and then chopped into short fibers by ball milling for 1 h in ethanol.
Preparation of BG Powder (BGP)
The same glass precursors as those referred earlier were stirred at room temperature for 48 h and aged at 608C for 48 h. The formed gel was dried in an oven at 708C for 48 h and crushed into powders. The powders were heat treated at 7008C for 1 h at a rate of 28C/min.
Fabrication of PCL/BG Composite
PCL (Sigma-Aldrich, USA, M n 5 80,000) was dissolved in tetrahydrofuran (THF; Sigma-Aldrich, USA) by stirring for 24 h. The BG powders or nanofibers were added to the PCL/THF solution and further stirred for 24 h. The ratio of the PCL/BG to the THF solvent was 10% w/v, and the ratio of the BG to the PCL/BG composite was 20% by weight (10, 20 , and 30% for alkaline phosphatase (ALP) activity test). The mixture was poured into a polyethylene container and then dried in the air. After the evaporation of the THF solvent, the PCL/BG composite was obtained in the form of a film with a thickness of 0.2 mm.
Characterization
The morphologies of the sol-gel-derived BGP, electrospun BGNF, and PCL/BG composite were observed using scanning electron microscopy (SEM, JSM 5410LV, JEOL, Tokyo, Japan). The cross-sectional images of the composite specimens were also observed. Mechanical tests were performed using a tensile test machine (Model 5565, Instron, Danvers, MA) at an extension rate of 5 mm/min. The specimens were dumbbell-shaped films with a thickness of 0.2 mm, a gauge length of 20 mm, and an inner width of 10 mm.
To examine the biological properties of the PCL/BG composites, in vitro cell tests were conducted using preosteoblast cell line (MC3T3-E1; ATCC, CRL-2593; USA). Before seeding the cells, the specimens were sterilized with 70% ethanol for 30 min, and dried on a clean bench under UV irradiation. The preincubated cells were seeded onto the specimens at a density of 3 3 10 4 cells/cm 2 , and then cultured in culture media consisting of a-modified minimum essential medium (a-MEM, Welgene Co., Korea) supplemented with 10% fetal bovine serum (FBS; GIBCO, USA), 1% penicillin-streptomycin, 1, 3, and 10 mM bglycerol phosphate, and 50 lg/mL ascorbic acid in a humidified incubator with 5% CO 2 at 378C. The morphology of the attached cells on the specimens was observed using confocal laser scanning microscopy (CLSM, Carl Zeiss-LSM510) after 4-h culture. The cell viability was examined using the MTS assay after 5-day culture. The quantity of formazan product, as measured by the absorbance read at 490 nm using a microreader (Biorad, Model 550, USA), is directly proportional to the number of living cells in the culture. The ALP activity was evaluated in the cells on the specimens containing the various amounts of BG (10, 20 , and 30 wt %). The measurement was performed using a p-nitrophenyl phosphate (pNPP, Sigma-Aldrich, UK). This colorimetric assay involved the measurement of the p-nitrophenol (pNP) converted from pNPP in the presence of ALP, where the rate of pNP production is proportional to the ALP activity. The production of pNP was determined by the absorbance at 405 nm measured using a microreader after 10-day culture.
In vivo animal experiments were also performed to examine the bone regenerative potential of the PCL/BGNF composite using 10 male Sprague-Dawley albino rats (13 weeks, weighing 500-600 g). Two calvarial bone defects (5 mm in diameter) in each rat were created as described by Bosch et al. 14 The circular defects were made bilaterally on both sides of the midline of the parietal bone using a trephine bur, with care being taken to prevent the perforation of the dura mater. Fifteen of the bone defects were covered with PCL/BGNF composite membranes (n 5 10) or pure PCL membranes (n 5 5), and the remaining defects (n 5 5) were left untreated as controls. The animals were killed 3 weeks after surgery and the tissues around the defects were extracted. The extracted samples were rinsed with saline solution and fixed in 10% neutral formaldehyde solution. The fixed samples were decalcified, embedded in paraffin, and made into blocks. Paraffin sections were prepared from the blocks and stained in Masson-Trichrome. Microscopic images of the sections were obtained using a transmission and polarized light microscope (Olympus BX51, Olympus Corp., Tokyo, Japan), and the percentage of regenerated bone areas with respect to the total defect areas was calculated using a computerized image analysis system (Diagnostic Instrument, MI).
The results of the biological and mechanical tests were expressed as means 6 standard deviations. The statistical analysis was performed by using a one-way analysis of variance with statistical significances at *p \ 0.05 and **p \ 0.01. Figure 1 shows the morphology of the sol-gel-derived BGP and electrospun BGNF after heat treatment. The sol-gel derived BGP had an irregular shape and its particle size distribution was not uniform, as shown in Figure 1 (a). The average particle size of the BGP was 4 lm (63 lm). In Figure 1(b,c) , it can be seen that continuous nanofibers were successfully generated without any beads through the electrospinning process and that the fibrous morphology was well maintained during the heat treatment. The average diameter of the fibers was 450 nm (680 nm).
RESULTS

BG Morphology
PCL/BG Composite Morphology
The surface SEM micrographs of the PCL/20 wt % BGP and PCL/20 wt % BGNF composites are shown in Figure 2 . Both types of composite revealed porous surface features, which were formed during the drying and evaporation of the sol mixtures. BG particles were not found on the surface of the PCL/BGP composite, as shown in Figure 2(a) , whereas BGNFs were clearly seen both on the surface of the PCL/BGNF and inside through the pores, with the latter being incorporated into the PCL matrix in the form of a net, as shown in Figure 2(c) . The amount of exposed BGs would be expected to influence the bioactivity of the composites in a physiological environment, as will be discussed later. Figure 2(b,d) shows the SEM cross-sectional images of the PCL/BG composites. The BGPs were agglomerated sporadically and were not distributed uniformly in the PCL matrix, as shown in Figure 2(b) . In addition, the BGPs were not completely bound by the PCL matrix when compared with the BGNFs. In contrast to the BGPs, the BGNFs were well dispersed and compactly included in the PCL matrix, as shown in Figure 2(d) .
Mechanical Properties
The elastic modulus and tensile strength of the PCL/BGP and PCL/BGNF composites obtained from the tensile tests are shown in Figure 3 compared with those of the PCL control. The stiffening effect of the BGP in the composite was not significant (p [ 0.05), whereas the elastic modulus of the PCL/BGNF composite was significantly increased when compared with that of the pure PCL control (**p \ 0.01) and the PCL/BGP composite (*p \ 0.05). There was no significant difference in the tensile strength of the specimens as shown in Figure 3 .
In Vitro Osteoblastic Activity
The biological properties of the PCL/20 wt % BGP and PCL/20 wt % BGNF composites were characterized by in vitro cell tests using the MC3T3-E1 cell line. Improved cell attachment, proliferation, and differentiation were observed as compared with the pure PCL control group. The CLSM images of MC3T3 cells cultured for 4 h are The degree of cell proliferation determined by the MTS method is presented in Figure 5 . Both the PCL/BGP (*p \ 0.05) and PCL/BGNF (**p \ 0.01) composites showed higher levels of cell viability compared with the PCL control. However, there was no significant difference in the proliferation of the cells with regard to the type of reinforced BG (p [ 0.05). These results indicate that the biocompatibility of the PCL matrix was enhanced by the reinforcing BGP or BGNF. Figure 6 shows the ALP activity of the cells cultured on the specimens for 10 days. Regardless of the BG content and the type of reinforced BG, the ALP activity level of the PCL/BG composite was higher than that of the PCL control, which means that the BG imparted bioactivity to the composite. In the PCL/BG composites, the ALP activity was remarkably influenced by the BG content and the type of reinforced BG. The ALP activity of the composites initially increased with increasing BG content, reaching the highest level at a BG content of 20 wt %, and subsequently decreased at a BG content of 30 wt %. At the same BG content of 20 wt %, the PCL/BGNF composite showed a considerably higher level of bioactivity than the PCL/BGP composite (**p \ 0.01).
In Vivo Bone Formation
The optical micrographs of the Masson-Trichrome-stained tissue sections are shown in Figures 7 and 8 . At 3 weeks after surgery, there was no evidence of inflammatory responses at any of the defect sites, and the remaining implanted materials were observed. The empty control defect was partially filled with thin newly formed bone and fibrous tissues. The appearance of the newly formed bone under the PCL membrane was analogous to that in the case of the empty defect. In contrast to the untreated defect and the PCL membrane group, relatively thick new bone was regenerated under the PCL/BGNF composite membrane. Furthermore, a larger amount of new bone was formed at the center of the defect and at the defect margin in the PCL/BGNF group, resulting in complete defect closure. Figure 8 shows the significant difference in the new bone formation at the center of the defect site in each sample. When the defect was covered with the PCL/BGNF composite membrane, the new bone growth progressed further with sufficient bone thickness compared with the untreated defect and PCL membrane groups. The percentage regenerated bone area calculated in the histomorphometric analysis is indicated in Figure 9 . The percentage regenerated bone area in the case of the PCL/BGNF composite membrane was higher than that in the case of both the untreated defect (*p \ 0.05) and PCL membrane (**p \ 0.01). There was no significant difference between the untreated defect group and PCL membrane group.
DISCUSSION
In this study, a PCL/BGNF composite was fabricated and characterized, with the goal of enhancing the biological and mechanical properties of the PCL/BG composite system as compared with the PCL/BGP composite. For it to be used as a bone regenerative material, a PCL/BG composite needs to have better biocompatibility, bioactivity, and mechanical stability, which can be achieved by reinforcing it with BGNF. Significant differences were found between the PCL/BGP composite and PCL/BGNF composite in the results obtained in this study. These differences are basically caused by the dimensional and morphological characteristics of the BG fillers.
The BGNFs were successfully generated with a comparatively regular diameter on the nanoscale (Figure 1) , although there were some deviations in their diameters because of the unavoidable differences in the process conditions during the electrospinning process. The electrospun fibers were bead free and maintained their fibrous morphology after heat treatment. On the other hand, the sol-gelderived microscale BG powders had irregular shapes and poor size distribution (Figure 1) . Because BGNF has sizes on the submicron scale, its specific surface area is much larger than that of BGP. The fact that BGNF has a large surface area implies that it can interact sufficiently with the organic matrix and react efficiently with the physiological environment. Moreover, BGNF can be distributed evenly in the PCL matrix because of its uniform shape and size distribution, which is in contrast to the case of micron-sized BGP. The enhanced biological and mechanical properties of the PCL/BGNF composite are mainly attributed to these differences.
The PCL has too low stiffness, which would restrict its application in hard tissues. In a PCL composite, it is possible to improve its stiffness with relatively small mechanical strength reduction using a proper amount of inorganic fillers. 8 The normally low stiffness of the PCL was also improved by incorporating the BGNF fillers ( Figure 3) . It is well known that fibers are mechanically more effective in achieving a stiff composite than particles and that rigid inorganic fillers increase the stiffness of the composites to an extent, which depends on the composite structure, volume fraction, shape and size of the fillers. 15 The results of the mechanical tests in this study showed a different stiffening effect according to the type of filler. In the case of the PCL/BGP composite, the stiffening effect of the BGP fillers was not significant. Indeed, in some cases, the elastic modulus decreased with the introduction of the BGP fillers. In contrast to the BGP fillers, the BGNF fillers considerably increased the elastic modulus of the PCL/BGNF composite. This difference between BGP and BGNF can be explained by the size and morphological effect of the latter. BGP is poorly incorporated into the PCL matrix with some agglomeration, whereas BGNF has a much higher level of interfacial interaction and strong bonding with the PCL matrix, as described in Figure 2 . Because of the relatively good interface quality, the stresses are efficiently transferred between the fillers and matrix, with the result that the stiffness of the composite is increased. 16 In the current work, the optimum BG content for obtaining high osteoblastic activity, which is a key factor in osteoblastic cell differentiation and bone regeneration, was found by the ALP activity test. The test was performed using specimens incorporating BGP or BGNF with contents of 10, 20, and 30 wt %, along with pure PCL as a control ( Figure 6 ). All of the composite specimens revealed higher levels of bioactivity than the PCL control. This was mainly attributed to the ability of the BG to induce the apatite formation and stimulate the osteoblastic cell responses. In physiological environment, BG releases calcium and phosphate ions, and further induces a formation of calcium phosphate precipitation. 17 As regards, the variation in the ALP activity with the BG content in the composites, the PCL/BG composites with a BG content of 20 wt % exhibited the highest level of bioactivity (in the case of both BGNF and BGP). The composites with a higher content of BG than 20 wt %, however, showed a decrease in their ALP activity, which is considered to be related to the detrimental change in the properties of the culturing medium, such as the pH and ion concentration. Based on the ALP activity result, the BG content in this study was fixed at 20 wt % for all other evaluations. At this BG content, the cell viability of the PCL/BG composite was higher than that of the pure PCL, and there was no significant difference between the PCL/BGP and PCL/BGNF composites ( Figure 5 ). This implies that the cells proliferated better on the composites containing BG, but that the type of BG had no critical effect on the cell proliferation for up to 5 days. However, a significant difference between BGP and BGNF was found in the ALP activity result. The ALP activity was further enhanced in the PCL/BGNF composite at the same BG content of 20 wt %. This enhanced osteoblastic activity of the PCL/BGNF composite is deemed to be due to the existence of a larger number of BGNFs that are exposed to the composite surface through the porous PCL matrix (Figure 2) . In a physiological environment, the dissolution and precipitation of ions can actively occur through the large surface of the nanoscale-roughened BGNFs, which enables them to interact with osteoblastic cells effectively. The excellent bioactivity of the BGNF has been reported elsewhere for polymer/BG fiber composites. [18] [19] The results of the in vivo animal tests also showed that the PCL/BGNF composite demonstrated good biocompatibility and bone-forming ability (Figures 7-9) . No inflammatory response was found on the tissue samples in the PCL/BGNF composite group. When the defect was covered with a PCL/BGNF composite membrane, thick new bone was generated after 3 weeks. In comparison with the empty defect and pure PCL groups, new bone was regenerated over a larger defect area at the same period of time in the PCL/BGNF composite group. This confirms well with high ALP activity (in vitro) of a PCL/BGNF composite and indicates that adding BGNF to PCL stimulates and accelerates new bone formation.
The current results clearly showed the beneficial effect of the BGNF on the biological properties of the PCL composite, in terms of its stimulation of the in vitro osteoblastic activity and acceleration of bone formation in a rat calvarial defect. As compared with the conventional particulate form of BG, the newly developed nanofibrous BG (BGNF) is, thus, considered to have good potential for use as a filler for degradable polymers, including PCL/BGNF composites, in the bone regeneration area.
CONCLUSIONS
A PCL/BGNF composite was fabricated using sol-gelderived electrospun BGNFs. The BGNFs were reinforced more uniformly and better dispersed than the BGPs in the PCL matrix. The incorporation of the BGNF also significantly enhanced the biocompatibility, osteoblastic activity in vitro, and elastic modulus of the composite when compared with the BGP. Moreover, the PCL/BGNF composite exhibited good biocompatibility and bone-forming ability in vivo. These improved properties of the composite in this study are primarily related to the nanoscaled fibrous structure of the incorporated BG. It is concluded that the PCL/ BGNF composite is suitable for use as a bone regenerative material.
